Equities research analysts expect FibroGen Inc (NASDAQ:FGEN) to report ($0.58) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for FibroGen’s earnings, with the highest EPS estimate coming in at $0.57 and the lowest estimate coming in at ($1.07). FibroGen reported earnings per share of $1.26 during the same quarter last year, which would indicate a negative year over year growth rate of 146%. The company is expected to issue its next earnings report on Thursday, August 13th.

On average, analysts expect that FibroGen will report full year earnings of ($1.61) per share for the current year, with EPS estimates ranging from ($2.65) to $0.87. For the next financial year, analysts expect that the business will post earnings of ($0.61) per share, with EPS estimates ranging from ($2.35) to $0.83. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow FibroGen.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.50). FibroGen had a negative return on equity of 19.32% and a negative net margin of 42.75%. The firm had revenue of $24.40 million during the quarter, compared to the consensus estimate of $72.58 million. During the same quarter in the prior year, the business earned ($0.53) earnings per share. FibroGen’s revenue for the quarter was up 2.3% on a year-over-year basis.

Several equities analysts have weighed in on FGEN shares. SVB Leerink lowered their target price on FibroGen from $85.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, May 8th. Bank of America initiated coverage on FibroGen in a research note on Monday, April 27th. They set a “neutral” rating and a $45.00 target price on the stock. Citigroup lowered their target price on FibroGen from $65.00 to $51.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. Cowen initiated coverage on FibroGen in a research note on Friday, May 1st. They set a “market perform” rating and a $40.00 target price on the stock. Finally, TheStreet cut FibroGen from a “c-” rating to a “d” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $56.00.

NASDAQ:FGEN traded up $0.19 during trading hours on Monday, hitting $40.59. 538,270 shares of the company traded hands, compared to its average volume of 725,206. The company has a quick ratio of 11.01, a current ratio of 11.14 and a debt-to-equity ratio of 0.07. The firm’s 50-day simple moving average is $36.97 and its 200-day simple moving average is $39.30. FibroGen has a one year low of $22.65 and a one year high of $48.95. The company has a market cap of $3.60 billion, a PE ratio of -30.75 and a beta of 1.48.

In other FibroGen news, CEO Enrique A. Conterno acquired 8,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average price of $36.29 per share, with a total value of $290,320.00. Following the completion of the acquisition, the chief executive officer now owns 60,000 shares of the company’s stock, valued at $2,177,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Pat Cotroneo sold 3,928 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $39.68, for a total value of $155,863.04. Following the transaction, the chief financial officer now directly owns 271,060 shares of the company’s stock, valued at approximately $10,755,660.80. The disclosure for this sale can be found here. 3.39% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Victory Capital Management Inc. lifted its position in FibroGen by 2.3% in the 4th quarter. Victory Capital Management Inc. now owns 12,059 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 270 shares during the last quarter. Sei Investments Co. lifted its position in FibroGen by 16.3% in the 4th quarter. Sei Investments Co. now owns 35,149 shares of the biopharmaceutical company’s stock worth $1,508,000 after buying an additional 4,933 shares during the last quarter. Acadian Asset Management LLC bought a new stake in FibroGen in the 4th quarter worth approximately $152,000. Quantbot Technologies LP lifted its position in FibroGen by 130.6% in the 4th quarter. Quantbot Technologies LP now owns 3,297 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,867 shares during the last quarter. Finally, Martingale Asset Management L P lifted its position in FibroGen by 65.7% in the 4th quarter. Martingale Asset Management L P now owns 19,421 shares of the biopharmaceutical company’s stock worth $833,000 after buying an additional 7,703 shares during the last quarter. 71.66% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Story: Neutral Rating

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.